Shire PLC (NASDAQ:SHPG) – Equities research analysts at SunTrust Banks cut their Q4 2018 earnings per share estimates for shares of Shire in a research report issued to clients and investors on Wednesday, October 17th. SunTrust Banks analyst J. Boris now anticipates that the biopharmaceutical company will post earnings of $3.81 per share for the quarter, down from their previous forecast of $3.87. SunTrust Banks also issued estimates for Shire’s FY2022 earnings at $19.46 EPS.

Shire (NASDAQ:SHPG) last released its quarterly earnings results on Tuesday, July 31st. The biopharmaceutical company reported $3.88 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.67 by $0.21. The business had revenue of $3.92 billion during the quarter. Shire had a net margin of 31.06% and a return on equity of 13.22%. The business’s quarterly revenue was up 4.6% compared to the same quarter last year. During the same period in the previous year, the company posted $3.73 earnings per share.

Other equities analysts have also issued reports about the stock. BidaskClub raised shares of Shire from a “sell” rating to a “hold” rating in a research report on Tuesday, July 3rd. ValuEngine raised shares of Shire from a “sell” rating to a “hold” rating in a research report on Friday, August 24th. Berenberg Bank lowered shares of Shire from a “buy” rating to a “hold” rating in a research report on Friday, September 7th. Cantor Fitzgerald set a $222.00 price objective on shares of Shire and gave the company a “buy” rating in a research report on Tuesday, July 31st. Finally, Royal Bank of Canada set a $188.00 price objective on shares of Shire and gave the company a “buy” rating in a research report on Thursday, July 19th. Nine research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $196.73.

SHPG stock opened at $175.01 on Friday. The stock has a market cap of $53.91 billion, a price-to-earnings ratio of 11.66, a PEG ratio of 1.58 and a beta of 1.19. Shire has a one year low of $123.73 and a one year high of $182.36. The company has a quick ratio of 1.02, a current ratio of 1.55 and a debt-to-equity ratio of 0.45.

A number of institutional investors and hedge funds have recently bought and sold shares of SHPG. Centaurus Financial Inc. acquired a new stake in shares of Shire during the 2nd quarter worth approximately $102,000. North Star Investment Management Corp. acquired a new stake in shares of Shire during the 2nd quarter worth approximately $106,000. Rehmann Capital Advisory Group grew its stake in shares of Shire by 226.9% during the 2nd quarter. Rehmann Capital Advisory Group now owns 680 shares of the biopharmaceutical company’s stock worth $115,000 after purchasing an additional 472 shares during the period. Valeo Financial Advisors LLC acquired a new stake in shares of Shire during the 2nd quarter worth approximately $129,000. Finally, Cornerstone Wealth Management LLC acquired a new stake in shares of Shire during the 2nd quarter worth approximately $145,000. 17.85% of the stock is owned by institutional investors.

The firm also recently declared a dividend, which was paid on Friday, October 19th. Shareholders of record on Friday, September 7th were given a dividend of $0.168 per share. The ex-dividend date was Thursday, September 6th. Shire’s dividend payout ratio is presently 2.24%.

Shire Company Profile

Shire plc, a biotechnology company, researches, develops, licenses, manufactures, markets, distributes, and sells medicines for rare diseases and other specialized conditions worldwide. The company offers products in therapeutic areas, including hematology, genetic diseases, neuroscience, immunology, internal medicine, ophthalmology, and oncology.

Featured Article: Diversification For Individual Investors

Earnings History and Estimates for Shire (NASDAQ:SHPG)

Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.